In vitro tests for aerosol deposition. III: Effect of inhaler insertion angle on aerosol deposition

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Volumn 26, Issue 3, 2013, Pages 145-156

  Delvadia, Renish R ^a   Worth Longest, P ^a,b   Hindle, Michael ^a   Byron, Peter R ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b Virginia Commonwealth University   (United States)

Author keywords

CFD modeling; dry powder inhaler; in vitro deposition; insertion angle; metered dose inhaler; Mouth throat airway model

Indexed keywords

SALBUTAMOL; SALBUTAMOL SULFATE;

AEROSOL; ARTICLE; COMPUTATIONAL FLUID DYNAMICS; DRUG DELIVERY SYSTEM; DRY POWDER INHALER; IN VITRO STUDY; INHALER; METERED DOSE INHALER;

AEROSOLS; ALBUTEROL; DRUG DELIVERY SYSTEMS; DRY POWDER INHALERS; EQUIPMENT DESIGN; HUMANS; HYDRODYNAMICS; LUNG; METERED DOSE INHALERS; MODELS, ANATOMIC; NEBULIZERS AND VAPORIZERS; PARTICLE SIZE; TISSUE DISTRIBUTION;

EID: 84878383421     PISSN: 19412711     EISSN: 19412703     Source Type: Journal    
DOI: 10.1089/jamp.2012.0989     Document Type: Article

References (34)

1. Newman S, Anderson P, Byron P, Dalby R, and Peart J: Respiratory Drug Delivery: Essential Theory and Practice. RDD Online/Virginia Commonwealth University, Richmond, VA; 2009.
2. Borgström L, Olsson B, and Thorsson L: Degree of throat deposition can explain the variability in lung deposition of inhaled drugs. J Aerosol Med. 2006;19:473-483.
3. Burnell PK, Asking L, Borgström L, Nichols SC, Olsson B, Prime D, and Shrubb I: Studies of the human oropharyngeal airspaces using magnetic resonance imaging IV-the oropharyngeal retention effect for four inhalation delivery systems. J Aerosol Med. 2007;20:269-281.
4. Brillet PY, Fetita CI, Saragaglia A, Brun AL, Beigelman-Aubry C, Preteux F, and Grenier PA: Investigation of airways using MDCT for visual and quantitative assessment in COPD patients. Int J Chron Obstruct Pulmon Dis. 2008;3:97-107.
5. Cherng C-H, Wong C-S, Hsu C-H, and Ho S-T: Airway length in adults: estimation of the optimal endotracheal tube length for orotracheal intubation. J Clin Anesth. 2002;14: 271-274.
6. Ehtezazi T, Horsfield MA, Barry PW, and O'Callaghan C: Dynamic change of the upper airway during inhalation via aerosol delivery devices. J Aerosol Med. 2004;17:325-334.
7. Fadl A, Wang J, Zhang Z, and Sung Cheng Y: Effects of MDI spray angle on aerosol penetration efficiency through an oral airway cast. J Aerosol Sci. 2007;38:853-864.
8. Ehtezazi T, Horsfield MA, Barry PW, Goodenough P, and O'Callaghan C: Effect of device inhalational resistance on the three-dimensional configuration of the upper airway. J Pharm Sci. 2005;94:1418-1426.
9. McRobbie DW, and Pritchard, SE: Studies of the human oropharyngeal airspaces using magnetic resonance imaging. III. The effects of device resistance with forced maneuver and tidal breathing on upper airway geometry. J Aerosol Med. 2005;18:325-336.
10. Newman SP, Hollingworth A, and Clark AR: Effect of different modes of inhalation on drug delivery from a dry powder inhaler. Int J Pharm. 1994;102:127-132.
11. Xi J, and Longest PW: Effects of oral airway geometry characteristics on the diffusional deposition of inhaled nanoparticles. J Biomech Eng. 2008;130:011008.
12. Longest PW, Hindle M, and Das Choudhuri S: Effects of generation time on spray aerosol transport and deposition in models of the mouth-throat geometry. J Aerosol Med Pulm Drug Del. 2009;22:67-83.
13. Yeh HC, Phalen RF, and Raabe OG: Factors influencing the deposition of inhaled particles. Environ Health Perspect. 1976;15:147-156.
14. Longest PW, and Hindle M: Evaluation of the Respimat Soft Mist Inhaler using a concurrent CFD and in vitro approach. J Aerosol Med Pulm Drug Del. 2009;22:99-112.
15. Newman SP, Wilding IR, and Hirst PH: Human lung deposition data: the bridge between in vitro and clinical evaluations for inhaled drug products? Int J Pharm. 2000;208:49-60.
16. Al-Showair RA, Tarsin WY, Assi KH, Pearson SB, and Chrystyn H: Can all patients with COPD use the correct inhalation flow with all inhalers and does training help? Respir Med. 2007;101:2395-2401.
17. Barthwal MS, Katoch CD, and Marwah V: Impact of optimal asthma education programme on asthma morbidity, inhalation technique and asthma knowledge. J Assoc Physicians India. 2009;57:574-576, 579.
18. McFadden ER Jr: Improper patient techniques with metered dose inhalers: clinical consequences and solutions to misuse. J Allergy Clin Immunol. 1995;96:278-283.
19. Giraud V, and Roche N: Misuse of corticosteroid metereddose inhaler is associated with decreased asthma stability. Eur Respir J. 2002;19:246-251.
20. van Beerendonk I, Mesters I, Mudde AN, and Tan T: Assessment of the inhalation technique in outpatients with asthma or chronic obstructive pulmonary disease using a metered-dose inhaler or dry powder device. J Asthma. 1998;35:273-279.
21. Rootmensen GN, van Keimpema ARJ, Jansen HM, and de Haan RJ: Predictors of incorrect inhalation technique in patients with asthma or COPD: a study using a validated videotaped scoring method. J Aerosol Med Pulm Drug Del. 2010;23:323-328.
22. Longest PW, Hindle M, Das Choudhuri S, and Byron PR. Developing a better understanding of spray system design using a combination of CFD modeling and experiment. In: RN Dalby, PR Byron, J Peart, JD Suman, SJ Farr, and PM Young, (eds). Proceedings of Respiratory Drug Delivery 2008. Davis Healthcare International Publishing, River Grove, IL; pp. 151-163, 2008.
23. Delvadia RR, Longest PW, and Byron PR: In vitro tests for aerosol deposition. I: Scaling a physical model of the upper airways to predict drug deposition variation in normal humans. J Aerosol Med Pulm Drug Del. 2012;25:32-40.
24. Xi J, and Longest PW: Transport and deposition of microaerosols in realistic and simplified models of the oral airway. Ann Biomed Eng. 2007;35:560-581.
25. Yeh HC, and Schum GM: Models of human lung airways and their application to inhaled particle deposition. Bull Math Biol. 1980;42:461-480.
26. Tian G, Longest P, Su G, Walenga RL, and Hindle M: Development of a stochastic individual path (SIP) model for predicting the tracheobronchial deposition of pharmaceutical aerosols: effects of transient inhalation and sampling the airways. J Aerosol Sci. 2011;42:781-799.
27. Delvadia RR, Byron PR, Longest PW, and Hindle M: In vitro prediction of regional drug deposition from dry powder inhalers. In: RN Dalby, PR Byron, J Peart, JD Suman, SJ Farr, and PM Young, (eds). Proceedings of Respiratory Drug Delivery 2010, Vol III. Davis Healthcare International Publishing, River Grove, IL and www .rddonline.com; pp. 907-912, 2010.
28. Cheng YS, Fu CS, Yazzie D, and Zhou Y: Respiratory deposition patterns of salbutamol pMDI with CFC and HFA-134a formulations in a human airway replica. J Aerosol Med. 2001;14:255-266.
29. Hochrainer D, Holz H, Kreher C, Scaffidi L, Spallek M, and Wachtel H: Comparison of the aerosol velocity and spray duration of Respimat soft mist inhaler and pressurized metered dose inhalers. J Aerosol Med. 2005;18:273-282.
30. Longest PW, Tian G, Walenga RL, and Hindle M: Comparing MDI and DPI aerosol deposition using in vitro experiments and a new stochastic individual path (SIP) model of the conducting airways. Pharm Res. 2012;29:1670-1688.
31. Longest PW, Hindle M, Das Choudhuri S, and Xi J: Comparison of ambient and spray aerosol deposition in a standard induction port and more realistic mouth-throat geometry. J Aerosol Sci. 2008;39:572-591.
32. Xi J, Longest PW, and Martonen TB: Effects of the laryngeal jet on nano-and microparticle transport and deposition in an approximate model of the upper tracheobronchial airways. J Appl Physiol. 2008;104:1761-1777.
33. Longest PW, Hindle M, Das Choudhuri S, and Byron PR: Numerical simulations of capillary aerosol generation: CFD model development and comparisons with experimental data. Aerosol Sci Tech. 2007;41:952-973.
34. Delvadia RR, Hindle M, Longest PW, and Byron PR: In vitro tests for aerosol deposition. II: IVIVCs for different dry powder inhalers in normal adults. J Aerosol MedPulm Drug Del. 2012 (in press).